• home
  • about us
    • the advantage
    • key facts
    • where we are
    • where we invest
    • management team
    • funds
  • portfolio
    • companies
    • CEOs
  • news
  • investments
    • focus
      • prevention & nutraceuticals
      • medical foods OTC, Rx
      • enabling technologies
      • brands & channels
      • diagnostics
    • criteria
    • process
  • your business
  • careers
  • contact us
    • the bahamas
    • united kingdom
    • china
    • new zealand

portfolio

Phagenesis

Phagenesis is a neurostimulation device company that has developed the first clinically proven treatment for dysphagia (inability to swallow safely) following a stroke. Dysphagia occurs in about half stroke patients, and leads to poor nutrition that may require tube-feeding with associated higher risk of pneumonia and early death.

Phagenesis wins Bionow award for healthcare project of the year
2012-11-30
  • Phagenesis, which has developed a treatment for people with dysphagia - an inability to swallow safely which affects half of all stroke victims - won the healthcare project of the year category at last night's awards, which took place at The Mere Golf Resort and Spa, in Cheshire, U.K.

Read the full article...

Phagenesis Closes €7 Million Series B Financing Round
2011-10-04
  • Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.

Read the full article...

Daniel Green, Phagenesis:
 "Inventages brings talent, imagination and rigor to the process of identifying suitable investments."
www.phagenesis.com
www.phagenesis.com
Back to portfolio ...
Pierre Peteuil, Traceo
Pierre Peteuil, Traceo:
"Inventages invests in a long term strategy necessary for innovation." More...
Terms Print Top
© 2013 Inventages